Biofrontera Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $6.6 million, compared to a loss of $5.7 million in the same period last year. For the nine months ending September 30, 2025, the company recorded a net loss of $16.2 million, slightly improved from a loss of $16.4 million in the prior year. Total revenues for the third quarter were $7.0 million, down 22.5% from $9.0 million in Q3 2024, primarily due to decreased sales volume of its main product, Ameluz®. Year-to-date revenues were $24.6 million, a marginal decline from $24.7 million in the previous year.
The company’s operating expenses for the third quarter totaled $13.3 million, a decrease from $14.0 million in Q3 2024. The reduction in costs was largely attributed to a significant drop in costs of revenues from related parties, which fell by 60% to $1.9 million, reflecting a new cost structure under the amended license agreement for Ameluz®. However, selling, general, and administrative expenses increased by 19.3% to $10.0 million, driven by higher legal costs associated with ongoing patent claims.
In a significant strategic move, Biofrontera completed a transaction on October 20, 2025, acquiring the U.S. rights to Ameluz® and RhodoLED® from its former parent company, Biofrontera AG. This acquisition is expected to enhance the company's operational control and reduce costs, as it transitions to a new earnout model based on U.S. revenue performance. The company also finalized the sale of its Xepi product line on November 6, 2025, which is anticipated to generate up to $10 million in proceeds, further bolstering its financial position.
As of September 30, 2025, Biofrontera had cash and cash equivalents of $3.4 million, down from $5.9 million at the end of 2024. The company reported an accumulated deficit of $133.6 million. To address liquidity concerns, Biofrontera plans to explore external financing options and leverage the proceeds from the recent asset sale. The company has expressed uncertainty about its ability to continue as a going concern for the next twelve months, emphasizing the need for additional capital to sustain operations and support ongoing commercialization efforts.
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in dermatology, primarily commercializing photodynamic therapy (PDT) products for treating actinic keratosis. Its core offerings include the prescription drug Ameluz® and RhodoLED® lamps, used together for targeted skin lesion treatment. Biofrontera markets these products directly to dermatology providers in the U.S., leveraging exclusive licensing agreements and focusing on clinical development, regulatory compliance, and reimbursement to support adoption.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.